- Home
- TRML vs INVA Comparison
TRML vs INVA Comparison
Compare TRML & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- INVA
- Stock Information
- Founded
- TRML 2021
- INVA 1996
- Country
- TRML United States
- INVA United States
- Employees
- TRML N/A
- INVA N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- TRML Health Care
- INVA Health Care
- Exchange
- TRML Nasdaq
- INVA Nasdaq
- Market Cap
- TRML 1.2B
- INVA 1.3B
- IPO Year
- TRML N/A
- INVA 2004
- Fundamental
- Price
- TRML $47.90
- INVA $17.21
- Analyst Decision
- TRML Hold
- INVA Buy
- Analyst Count
- TRML 12
- INVA 5
- Target Price
- TRML $47.04
- INVA $35.60
- AVG Volume (30 Days)
- TRML 957.5K
- INVA 764.0K
- Earning Date
- TRML 11-06-2025
- INVA 11-05-2025
- Dividend Yield
- TRML N/A
- INVA N/A
- EPS Growth
- TRML N/A
- INVA N/A
- EPS
- TRML N/A
- INVA 0.53
- Revenue
- TRML N/A
- INVA $370,229,000.00
- Revenue This Year
- TRML N/A
- INVA $8.17
- Revenue Next Year
- TRML N/A
- INVA $12.06
- P/E Ratio
- TRML N/A
- INVA $32.27
- Revenue Growth
- TRML N/A
- INVA 12.02
- 52 Week Low
- TRML $11.56
- INVA $16.67
- 52 Week High
- TRML $48.27
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- TRML 91.37
- INVA 27.68
- Support Level
- TRML $47.83
- INVA $17.55
- Resistance Level
- TRML $47.94
- INVA $19.12
- Average True Range (ATR)
- TRML 0.11
- INVA 0.52
- MACD
- TRML -0.63
- INVA -0.21
- Stochastic Oscillator
- TRML 38.14
- INVA 3.57
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.